Skip to main content
Erschienen in: Autoimmunity Highlights 3/2014

01.12.2014 | Review Article

Assessment of patients with idiopathic inflammatory myopathies and isolated creatin-kinase elevation

verfasst von: L. Iaccarino, E. Pegoraro, L. Bello, S. Bettio, E. Borella, L. Nalotto, C. Semplicini, G. Sorarù, A. Ghirardello, A. Doria

Erschienen in: Autoimmunity Highlights | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Idiopathic inflammatory myopathies (IIM) are a group of diseases characterized by inflammation of the skeletal muscle. Weakness, mainly affecting the proximal muscles, is the cardinal muscular symptom in IIM. In patients with dermatomyositis, peculiar skin lesions are observed. The assessment of patients with IIM includes clinical and laboratory evaluation, and clinimetric measurements. Different tools have been proposed to measure muscular and extramuscular disease activity and damage in patients with IIM. A core set of measurements to use in clinical practice was recently proposed. Among laboratory features the increase of serum creatine kinase (CK) is considered a hallmark of muscle inflammation/damage. However, subjects with persistent CK elevation, without any evidence of a definite myopathy, are often seen in clinical practice and need a careful assessment. Indeed, CK blood levels can also increase in non-myopathic conditions, e.g. in case of intense physical exercise, assumption of some drugs (statins), muscular dystrophy, muscular trauma or in case of neuro-muscular disorders which all should be considered in the diagnostic work-up. The assessment of patients with IIM and hyperCKemia will be discussed in this paper.
Literatur
1.
Zurück zum Zitat Iaccarino L, Ghirardello A, Bettio S, Zen M, Gatto M, Punzi L, Doria A (2014) The clinical features, diagnosis and classification of dermatomyositis. J Autoimmun 48–49:122–127PubMedCrossRef Iaccarino L, Ghirardello A, Bettio S, Zen M, Gatto M, Punzi L, Doria A (2014) The clinical features, diagnosis and classification of dermatomyositis. J Autoimmun 48–49:122–127PubMedCrossRef
2.
Zurück zum Zitat Briani C, Doria A, Sarzi-Puttini P, Dalakas MC (2006) Update on idiopathic inflammatory myopathies. Autoimmunity 39:161–170PubMedCrossRef Briani C, Doria A, Sarzi-Puttini P, Dalakas MC (2006) Update on idiopathic inflammatory myopathies. Autoimmunity 39:161–170PubMedCrossRef
3.
Zurück zum Zitat Iaccarino L, Gatto M, Bettio S, Caso F, Rampudda M, Zen M, Ghirardello A, Punzi L, Doria A (2013) Overlap connective tissue disease syndromes. Autoimmun Rev 12:363–373PubMedCrossRef Iaccarino L, Gatto M, Bettio S, Caso F, Rampudda M, Zen M, Ghirardello A, Punzi L, Doria A (2013) Overlap connective tissue disease syndromes. Autoimmun Rev 12:363–373PubMedCrossRef
4.
Zurück zum Zitat Hervier B, Devilliers H, Stanciu R et al (2012) Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmun Rev 12:2010–2017 Hervier B, Devilliers H, Stanciu R et al (2012) Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmun Rev 12:2010–2017
5.
6.
Zurück zum Zitat Yuan L, Yao L, Zhao L, Xia L, Shen H, Lu J (2013) Serum levels of soluble ST2 and interleukin-33 in patients with dermatomyositis and polymyositis. Clin Exp Rheumatol 31:428–432PubMed Yuan L, Yao L, Zhao L, Xia L, Shen H, Lu J (2013) Serum levels of soluble ST2 and interleukin-33 in patients with dermatomyositis and polymyositis. Clin Exp Rheumatol 31:428–432PubMed
7.
Zurück zum Zitat Ghirardello A, Bassi N, Palma L, Borella E, Domeneghetti M, Punzi L, Doria A (2013) Autoantibodies in polymyositis and dermatomyositis. Curr Rheumatol Rep 15:335PubMedCrossRef Ghirardello A, Bassi N, Palma L, Borella E, Domeneghetti M, Punzi L, Doria A (2013) Autoantibodies in polymyositis and dermatomyositis. Curr Rheumatol Rep 15:335PubMedCrossRef
8.
Zurück zum Zitat Hengstman GJ, ter Laak HJ, Vree Egberts WT, Lundberg IE, Moutsopoulos HM, Vencovsky J, Doria A, Mosca M, van Venrooij WJ, van Engelen BG (2006) Anti-signal recognition particle autoantibodies: marker of a necrotizing myopathy. Ann Rheum Dis 65:1635–1638PubMedCrossRef Hengstman GJ, ter Laak HJ, Vree Egberts WT, Lundberg IE, Moutsopoulos HM, Vencovsky J, Doria A, Mosca M, van Venrooij WJ, van Engelen BG (2006) Anti-signal recognition particle autoantibodies: marker of a necrotizing myopathy. Ann Rheum Dis 65:1635–1638PubMedCrossRef
9.
Zurück zum Zitat Ghirardello A, Zampieri S, Iaccarino L, Tarricone E, Bendo R, Gambari PF, Doria A (2005) anti-Mi-2 antibodies. Autoimmunity 38:79–83PubMedCrossRef Ghirardello A, Zampieri S, Iaccarino L, Tarricone E, Bendo R, Gambari PF, Doria A (2005) anti-Mi-2 antibodies. Autoimmunity 38:79–83PubMedCrossRef
10.
Zurück zum Zitat Zampieri S, Ghirardello A, Iaccarino L, Tarricone E, Gambari PF, Doria A (2005) Anti-Jo-1 antibodies. Autoimmunity 38:73–78PubMedCrossRef Zampieri S, Ghirardello A, Iaccarino L, Tarricone E, Gambari PF, Doria A (2005) Anti-Jo-1 antibodies. Autoimmunity 38:73–78PubMedCrossRef
11.
Zurück zum Zitat Oddis CV, Rider LG, Reed AM et al (2005) International consensus guidelines for trials of therapies in idiopathic inflammatory myopathies. Arthritis Rheum 52:2607–2615PubMedCrossRef Oddis CV, Rider LG, Reed AM et al (2005) International consensus guidelines for trials of therapies in idiopathic inflammatory myopathies. Arthritis Rheum 52:2607–2615PubMedCrossRef
12.
Zurück zum Zitat Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first part). N Engl J Med 292:344–347PubMedCrossRef Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first part). N Engl J Med 292:344–347PubMedCrossRef
13.
Zurück zum Zitat Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second part). N Engl J Med 292:403–407PubMedCrossRef Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second part). N Engl J Med 292:403–407PubMedCrossRef
14.
Zurück zum Zitat Linklater H, Pipitone N, Rose MR, Norwood F, Campbell R, Salvarani C, Scott DL, Gordon P (2013) Classifying idiopathic inflammatory myopathies: comparing the performance of six existing criteria. Clin Exp Rheumatol 31:767–769PubMed Linklater H, Pipitone N, Rose MR, Norwood F, Campbell R, Salvarani C, Scott DL, Gordon P (2013) Classifying idiopathic inflammatory myopathies: comparing the performance of six existing criteria. Clin Exp Rheumatol 31:767–769PubMed
15.
Zurück zum Zitat Targoff IN, Miller FW, Medsger TA, Oddis CV (1997) Classification criteria for idiopathic inflammatory myopathies. Curr Opin Rheumatol 9:527–535PubMedCrossRef Targoff IN, Miller FW, Medsger TA, Oddis CV (1997) Classification criteria for idiopathic inflammatory myopathies. Curr Opin Rheumatol 9:527–535PubMedCrossRef
16.
Zurück zum Zitat Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senecal JL (2005) Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine 84:231–249PubMedCrossRef Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senecal JL (2005) Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine 84:231–249PubMedCrossRef
17.
Zurück zum Zitat Miller FW, Rider LG, Plotz PH, Isenberg DA, Oddis CV (2003) Diagnostic criteria for polymyositis and dermatomyositis. Lancet 362:1762–1763PubMedCrossRef Miller FW, Rider LG, Plotz PH, Isenberg DA, Oddis CV (2003) Diagnostic criteria for polymyositis and dermatomyositis. Lancet 362:1762–1763PubMedCrossRef
18.
Zurück zum Zitat Hoogendijk JE, Amato AA, Lecky BR et al (2004) 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 october 2003, Naarden, The Netherlands. Neuromuscul Disord 14:337–345PubMedCrossRef Hoogendijk JE, Amato AA, Lecky BR et al (2004) 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 october 2003, Naarden, The Netherlands. Neuromuscul Disord 14:337–345PubMedCrossRef
19.
Zurück zum Zitat Miller FW, Rider LG, Chung YL et al (2001) Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology 40:1262–1273PubMedCrossRef Miller FW, Rider LG, Chung YL et al (2001) Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology 40:1262–1273PubMedCrossRef
20.
Zurück zum Zitat Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N, Herbelin L, Barohn R, Isenberg D, Miller FW (2011) Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis. Arthritis Care Res 63:S118–S157CrossRef Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N, Herbelin L, Barohn R, Isenberg D, Miller FW (2011) Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis. Arthritis Care Res 63:S118–S157CrossRef
21.
Zurück zum Zitat Rider LG, Giannini EH, Harris-Love M et al (2003) Defining clinical improvement in adult and juvenile myositis. J Rheumatol 30:603–617PubMed Rider LG, Giannini EH, Harris-Love M et al (2003) Defining clinical improvement in adult and juvenile myositis. J Rheumatol 30:603–617PubMed
22.
Zurück zum Zitat Rider LG, Koziol D, Giannini EH et al (2010) Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res 62:465–472CrossRef Rider LG, Koziol D, Giannini EH et al (2010) Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res 62:465–472CrossRef
23.
Zurück zum Zitat Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, Symmons DP, Viner N, Zoma A (1993) The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 86:447–458PubMed Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, Symmons DP, Viner N, Zoma A (1993) The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 86:447–458PubMed
24.
Zurück zum Zitat Brewster LM, Mairuhu G, Sturk A, van Montfrans GA (2007) Distribution of creatine kinase in the general population: implications for statin therapy. Am Heart J 154:655–661PubMedCrossRef Brewster LM, Mairuhu G, Sturk A, van Montfrans GA (2007) Distribution of creatine kinase in the general population: implications for statin therapy. Am Heart J 154:655–661PubMedCrossRef
25.
Zurück zum Zitat Prelle A, Tancredi L, Sciacco M et al (2002) Retrospective study of a large population of patients with asymptomatic or minimally symptomatic raised plasmacreatine kinase levels. J Neurol 249:305–311PubMedCrossRef Prelle A, Tancredi L, Sciacco M et al (2002) Retrospective study of a large population of patients with asymptomatic or minimally symptomatic raised plasmacreatine kinase levels. J Neurol 249:305–311PubMedCrossRef
26.
Zurück zum Zitat Simmons Z, Peterlin BL, Boyer PJ, Towfighi J (2003) Muscle biopsy in the evaluation of patients with modestly elevated creatine kinase levels. Muscle Nerve 27:242–244PubMedCrossRef Simmons Z, Peterlin BL, Boyer PJ, Towfighi J (2003) Muscle biopsy in the evaluation of patients with modestly elevated creatine kinase levels. Muscle Nerve 27:242–244PubMedCrossRef
27.
Zurück zum Zitat Rowland LP, Willner J, DiMauro S, Miranda A (1980) Approaches to the membrane theory of Duchenne muscular dystrophy. In: Angelini C, Danieli GA, Fontanari D (eds) Muscular dystrophy-advances and new trends. Excerpta Medica, Amsterdam, pp 3–13 Rowland LP, Willner J, DiMauro S, Miranda A (1980) Approaches to the membrane theory of Duchenne muscular dystrophy. In: Angelini C, Danieli GA, Fontanari D (eds) Muscular dystrophy-advances and new trends. Excerpta Medica, Amsterdam, pp 3–13
28.
Zurück zum Zitat Vaughan CJ, Gotto AM Jr (2004) Update on statins: 2003. Circulation 17(110):886–892CrossRef Vaughan CJ, Gotto AM Jr (2004) Update on statins: 2003. Circulation 17(110):886–892CrossRef
29.
Zurück zum Zitat Kyriakides T, Angelini C, Schaefer J et al (2010) EFNS guidelines on the diagnostic approach to pauci- or asymptomatic hyperCKemia. Eur J Neurol 17:767–773PubMedCrossRef Kyriakides T, Angelini C, Schaefer J et al (2010) EFNS guidelines on the diagnostic approach to pauci- or asymptomatic hyperCKemia. Eur J Neurol 17:767–773PubMedCrossRef
30.
Zurück zum Zitat Rossi D, Vezzani B, Galli L et al (2014) A mutation in the CASQ1 GeneCauses a vacuolar myopathy with accumulation of sarcoplasmic reticulum proteinAggregates. Hum Mutat. doi:10.1002/humu.22631 Rossi D, Vezzani B, Galli L et al (2014) A mutation in the CASQ1 GeneCauses a vacuolar myopathy with accumulation of sarcoplasmic reticulum proteinAggregates. Hum Mutat. doi:10.​1002/​humu.​22631
31.
Zurück zum Zitat Fanin M, Nascimbeni AC, Aurino S, Tasca E, Pegoraro E, Nigro V, Angelini C (2009) Frequency of LGMD gene mutations in Italian patients with distinct clinical phenotypes. Neurology 21(72):1432–1435CrossRef Fanin M, Nascimbeni AC, Aurino S, Tasca E, Pegoraro E, Nigro V, Angelini C (2009) Frequency of LGMD gene mutations in Italian patients with distinct clinical phenotypes. Neurology 21(72):1432–1435CrossRef
32.
Zurück zum Zitat Morandi L, Angelini C, Prelle A, Pini A, Grassi B, Bernardi G, Politano L, Bruno C, De Grandis D, Cudia P, Citterio A (2006) High plasma creatine kinase: review of the literature and proposal for a diagnostic algorithm. Neurol Sci 27:303–311PubMedCrossRef Morandi L, Angelini C, Prelle A, Pini A, Grassi B, Bernardi G, Politano L, Bruno C, De Grandis D, Cudia P, Citterio A (2006) High plasma creatine kinase: review of the literature and proposal for a diagnostic algorithm. Neurol Sci 27:303–311PubMedCrossRef
Metadaten
Titel
Assessment of patients with idiopathic inflammatory myopathies and isolated creatin-kinase elevation
verfasst von
L. Iaccarino
E. Pegoraro
L. Bello
S. Bettio
E. Borella
L. Nalotto
C. Semplicini
G. Sorarù
A. Ghirardello
A. Doria
Publikationsdatum
01.12.2014
Verlag
Springer International Publishing
Erschienen in
Autoimmunity Highlights / Ausgabe 3/2014
Print ISSN: 2038-0305
Elektronische ISSN: 2038-3274
DOI
https://doi.org/10.1007/s13317-014-0063-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.